NCT06316479尚未招募不适用
A Prospective, Multi-Centre, Single-Arm First-In-Man Study to Evaluate the Safety and Performance of PTMC Dermal Filler for the Correction of Moderate to Severe Nasolabial Folds
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 120
- 主要终点
- Nasolabial fold severity
研究概览
简要总结
The goal of this clinical trial is to assess the safety and performance of the PTMC Dermal filler for treating moderate to severe nasolabial folds in adult men and women.
The main questions it aims to answer are:
- Does the PTMC dermal filler maintain its performance for a minimum of 6 months?
- Is the treatment considered safe for participants?
Participants will:
- Before treatment, the investigator will assess your medical history, medication usage, and satisfaction with your wrinkles/folds.
- You'll receive one injection of the PTMC Dermal filler during your initial visit.
- For 30 days post-injection, you'll keep a diary to note any reactions like pain, redness, or swelling at the injection site.
- At the 1-month follow-up, you can request a 'touch-up' of the filler, extending your participation in the study.
- Participants will visit the clinic a total of 8 times, including the initial treatment and 7 follow-up visits, spanning up to 18 months.
- Each visit will last approximately 60-90 minutes. The visits will be conducted in person.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 67 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female ≥18 years and £67 old.
- •Two fully visible bilateral nasolabial folds each with a Wrinkle Severity Rating Scale (WSRS) score of 3 or 4 that may be corrected with an injectable dermal filler.
- •If female and of childbearing potential: a negative urine pregnancy test + agreement to use adequate contraception.
- •Ability to understand and comply with the study requirements.
- •Willingness and ability to provide written informed consent.
- •Agree to refrain from seeking other treatment of nasolabial folds during the study.
- •Over the counter (OTC) wrinkle products or prescription wrinkle treatments, if used, shall be continued throughout the study in similar manner as performed prior to participation.
排除标准
- •Wrinkle Severity Rating Scale (WSRS) score of ≤ 2 on the right or left nasolabial fold.
- •Women who are pregnant or lactating or planning to become pregnant during the study.
- •Evidence of scar-related disease or delayed healing activity within the past 1 year.
- •History of keloid formation or hypertrophic scars.
- •Scars at the intended treatment sites.
- •Any infection or wound on the face.
- •Facial tattoo that may interfere with diagnosis.
- •Allergic history including anaphylaxis or multiple severe allergies to natural rubber latex or lidocaine.
- •Clinically significant organic disease including clinically significant cardiovascular, hepatic, pulmonary, neurologic, or renal disease or other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator preclude participation in the trial.
- •Aspirin, or nonsteroidal anti-inflammatory drugs within 1 week (7 days) prior to treatment.
- •Systemic (oral/injectable) corticosteroids or immunosuppressive medications within 30 days prior to treatment and topical steroids on the face within 14 days prior to trial start and throughout the study.
- •Concomitant anticoagulant therapy, antiplatelet therapy, biotherapy or history of bleeding disorders or connective tissue disorders.
- •Immunocompromised or immunosuppressed.
- •History of autoimmune diseases.
- •Anti-covid vaccination (RNA-based vaccines) within 2 weeks (14 days) prior to treatment.
- •Received any investigational product within 30 days prior to treatment.
- •Received prior dermabrasion, or botulinum toxins under the orbital rim (tear through) within 6 months (180 days) prior to entry into the study.
- •Received facelift within 2 years prior to treatment.
- •Previous tissue augmentation (bulking agents) for facial wrinkles and scars within 6 months at the mid-face.
- •Previous tissue augmentation with permanent implants.
- •Treatment of microdermabrasion or micro needling within the whole facial area within 3 months prior to treatment.
- •Laser treatment within the whole facial area within 6 months prior to treatment.
研究组 & 干预措施
Treatment group
Experimental
All participants will receive PTMC Dermal Filler.
干预措施: PTMC Dermal Filler (Device)
结局指标
主要结局
Nasolabial fold severity
时间窗: 6 months after treatment
The nasolabial fold severity is measured using the Wrinkles Severity Rating Scale (WSRS) by the investigator.
次要结局
- Nasolabial fold severity(1, 3, 9, 12, and 18 months after treatment)
- Safety (Adverse events)(until 18 months after treatment)
- Overall aesthetic improvement (by the investigator)(1, 3, 6, 9, 12, and 18 months after treatment)
- Subject satisfaction(1, 3, 6, 9, 12, and 18 months after treatment)
- Responder rate(1, 3, 6, 9, 12, and 18 months after treatment)
- Overall aesthetic improvement (by the subject)(1, 3, 6, 9, 12, and 18 months after treatment)
研究者
相似试验
已完成
1 期
Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109Scar PreventionCicatrixNCT01640912RXi Pharmaceuticals, Corp.15
已完成
3 期
An Efficacy and Safety Study of TheraFill® Versus KOKEN for 3 Months on Nasolabial FoldsNasolabial FoldsNCT01060943Sewon Cellontech Co., Ltd.73
已完成
1 期
Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109Scar PreventionCicatrixNCT01780077RXi Pharmaceuticals, Corp.15
终止
2 期
Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)Warm Autoimmune Hemolytic Anemia (wAIHA)NCT04661033Sanofi8
已完成
不适用
Assessment of the Safety and Efficacy of the Dermal Filler "mARG-01-17" in Facial Rejuvenation TherapyFacial RejuvenationNCT04643977Mesoestetic Pharma Group S.L.40